Patent ID: 8877229
Filing Date: 2014-11-04
Classification: A61K,A61P

Abstract:
1. A sustained release suspension composition for intravitreal administration consisting essentially of a plurality of microparticles suspended in a pharmaceutically acceptable liquid carrier comprising phosphate buffer saline (PBS) and a surfactant comprising sodium dodecyl sulfate (SDS), wherein the liquid carrier is suitable for intravitreal administration, wherein said microparticles comprise: (a) a biologically active anti-VEGF aptamer; and (b) poly(lactic acid) (PLA) or poly(lactic acid-co-glycolic acid) (PLGA) polymer and have a smooth, non-pitted external morphology, wherein said polymer has a monomer ratio of lactide:glycolide in the range of about 40:60 to 100:0; said suspension comprises 100-300 mg microparticles per mL of said liquid carrier; said microparticles release said biologically active anti-VEGF aptamer over a period of at least 40 days; said microparticles have a particle size distribution in the range of 10 μm to 45 μm in diameter; said microparticles comprise a PLA or PLGA polymeric material incorporating a core load of at least 7 wt % of said anti-VEGF aptamer and; said microparticles release said anti-VEGF aptamer at an initial burst of less than 15 wt % of said core load within 24 hours of administration.